Singapore, Sept. 28 -- Deep Origin and partners in the Pharmacological Research and Evaluation through Digital Integration and Clinical Trials Simulation (PREDICTS) consortium announced that their new drug safety prediction models are now being implemented by four organisations in a pilot programme.

The in silico ADMET (absorption, distribution, metabolism, excretion, toxicity) models will be used to assess and filter millions of compounds to prioritise the drug candidates worth advancing.

PREDICTS is part of the Advanced Research Projects Agency for Health (ARPA-H) Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) programme, which is led by Program Manager Michael Patterson.

The programme aims to revolut...